COVID largo y Cáncer: Posibles mecanismos fisiopatológicos de un agente oncogénico
Resumen
Recibido: 22/06/2024
Aceptado: 1/08/2024
Publicado en línea: 22/10/2024
Texto completo:
PDFReferencias
Guevara M, Baztan M, Burgui R, Ovies A, Menéndez A, Eciolaza M, et al. Supervivencia de los pacientes con cáncer en Navarra y comparación con España. An Sist Sanit Navar. 2023;46(2):e1042. DOI: 10.23938/ASSN.1042
Gaudet LA, Pillay J, Saba S, Zakaria D, Cheta N, Gardiner H, et al. Associations between SARS-CoV-2 infection and incidence of new chronic condition diagnoses: a systematic review. Emerg Microbes Infect. 2023;12(1). DOI: 10.1080/22221751.2023.2204166
Roel E, Pistillo A, Recalde M, et al. Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4?618?377 adults in Catalonia, Spain. Int J Cancer. 2022;150(5):782-794. DOI: 10.1002/ijc.33846
Borno HT, Kim M-O, Hong JC, Yousefi S, Lin A, Tolstykh I, et al. COVID-19 outcomes among patients with cancer: Observations from the University of California Cancer Consortium COVID-19 project outcomes registry. Oncologist. 2022;27(5):398–406. DOI: 10.1093/oncolo/oyac038
Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview [published correction appears in Diabetes Metab Syndr. 2022 May;16(5):102504] [published correction appears in Diabetes Metab Syndr. 2022 Dec;16(12):102660]. Diabetes Metab Syndr. 2021;15(3):869-875. DOI: 10.1016/j.dsx.2021.04.007
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations [published correction appears in Nat Rev Microbiol. 2023 Jun;21(6):408]. Nat Rev Microbiol. 2023;21(3):133-146. DOI: 10.1038/s41579-022-00846-2
Lasagna A, Albi G, Figini S, Basile S, Sacchi P, Bruno R, et al. Long-COVID in patients with cancer previously treated with early anti-SARS-CoV-2 therapies in an out-of-hospital setting: A single-center experience. Cancers (Basel). 2023;15(4):1269. DOI: 10.3390/cancers15041269
Harada T, Schmitz K, Helsper CW, Campbell G, Nekhlyudov L. Long-COVID and long-term cancer survivorship-Shared lessons and opportunities. Eur J Cancer Care (Engl). 2022;31(6):e13712. DOI: 10.1111/ecc.13712
Saini G, Aneja R. Cancer as a prospective sequela of long COVID-19. Bioessays. 2021;43(6):e2000331. DOI: 10.1002/bies.202000331
Costanzo M, De Giglio MAR, Roviello GN. Deciphering the Relationship between SARS-CoV-2 and Cancer. Int J Mol Sci. 2023;24(9):7803. DOI: 10.3390/ijms24097803
Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? [published online ahead of print, 2023 May 23]. Biochimie. 2023;213:130-138. DOI: 10.1016/j.biochi.2023.05.014
Rapti V, Tsaganos T, Vathiotis IA, Syrigos NK, Li P, Poulakou G. New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?. Vaccines (Basel). 2022;10(10):1607. DOI: 10.3390/vaccines10101607
Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients. Trans R Soc Trop Med Hyg. 2022;116(9):767-797. DOI: 10.1093/trstmh/trac015
DOI: https://www.doi.org/10.53766/AcBio/Se encuentra actualmente indizada en: | |||
![]() | ![]() | ![]() | ![]() |
![]() ![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() |
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.